RESOURCES

Explore Eurofins Discovery’s comprehensive CRO chemistry services, spanning Medicinal, Synthetic, Computational, and Analytical chemistry, from small-scale synthesis to full process development to enable rapid design-make-test-analyze (DMTA) cycles and accelerate your drug discovery programs.

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of small-molecule cytotoxic payloads.

Successful Translational Approach to Accelerate Discovery Programs

Streamline. Automate. Accelerate.

There are numerous drugs withdrawn from the market, assigned warnings or halted in development due to observations of idiosyncratic adverse drug reactions (IADRs).

Cytochrome P450 (CYP) enzymes play a central role in the metabolism of many therapeutic agents.

Eurofins Discovery’s SAFETYscan^®47 DataViz is a complementary, customizable and interactive dashboard designed to extract, visualize, and communicate SAFETYscan47 in vitro safety pharmacology results.

Number of Active Predictions

Across biopharma, the pursuit and exploration of molecular glues continues unabated due their potential to transform our ability to modulate disease-relevant proteins.

The HT-SpS platform, coupled with Eurofins Discovery’s expertise in biophysics and screening, represents a significant advancement in screening strategies.

Scalable, Affordable, Adaptable Kinase Solutions

Specialized Panel of Metabolic Receptors